STAT Plus: Halozyme?s lead drug fails; company will cut 55% of workforce in bid for profitability November 4, 2019 sandiegobiotech News Comments Off on STAT Plus: Halozyme?s lead drug fails; company will cut 55% of workforce in bid for profitability STAT Plus: Halozyme?s lead drug fails; company will cut 55% of workforce in bid for profitability Play Episode Pause Episode Mute/Unmute Episode Rewind 10 Seconds 1x Fast Forward 30 seconds 00:00 / Subscribe Share RSS Feed Share Link Embed Halozyme, a San Diego-based biotech, said that its lead drug, for pancreatic cancer, had failed to extend the lives of patients in a clinical trial. BiotechbiotechnologycancerSTAT Plus
News STAT Plus: Watch this company: Turning Point Therapeutics shares pop 57% after IPO April 17, 2019 sandiegobiotech News Comments Off on STAT Plus: Watch this company: Turning Point Therapeutics shares pop 57% after IPO A San Diego-based developer of targeted cancer drugs is hoping its medicine can shrink tumors in non-small cell lung cancer caused by specific genetic alterations. […]